Abivax (NASDAQ:ABVX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Guggenheim in a research note issued on Tuesday, Benzinga reports. They currently have a $175.00 price objective on the stock. Guggenheim’s price objective indicates a potential upside of 88.48% from the company’s current price.
Other research analysts have also recently issued reports about the stock. Barclays reiterated an “overweight” rating and set a $148.00 price target on shares of Abivax in a research report on Tuesday, September 22nd. Piper Sandler increased their price target on shares of Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Wedbush reduced their price target on shares of Abivax from $140.00 to $118.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Thursday. Finally, Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $156.69.
Abivax Stock Up 6.1%
Shares of ABVX stock traded up $5.36 during trading on Tuesday, hitting $92.85. The company had a trading volume of 1,125,540 shares, compared to its average volume of 1,427,089. The stock’s 50-day moving average is $105.79 and its two-hundred day moving average is $114.49. The stock has a market capitalization of $8.13 billion, a price-to-earnings ratio of -15.31 and a beta of 1.14. Abivax has a 52 week low of $69.81 and a 52 week high of $148.83.
Abivax (NASDAQ:ABVX – Get Free Report) last posted its quarterly earnings data on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. On average, research analysts predict that Abivax will post -4.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in Abivax in the second quarter worth $30,000. GHP Investment Advisors Inc. boosted its holdings in Abivax by 155.6% in the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after acquiring an additional 140 shares in the last quarter. Assetmark Inc. boosted its holdings in Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after acquiring an additional 260 shares in the last quarter. Troluce Capital Advisors LLC bought a new stake in Abivax in the second quarter valued at $133,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new stake in Abivax in the first quarter valued at $208,000. Institutional investors own 47.91% of the company’s stock.
About Abivax
Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.
Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.
Read More
- Five stocks we like better than Abivax
- IonQ’s Bold Expansion Could Leave Shareholders Paying the Price
- Powering Up: Applied Digital Execs Buy $6.7M in Stock
- Chip Stocks Are Sliding—Why Is Smart Money Buying?
- Adults Are Fueling a Toy Boom—These 4 Stocks Could Cash In
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
